BioRestorative Therapies (BRTX) shares were up past 5% in recent Monday premarket activity after the company said the Japanese Patent Office issued a notice of allowance for its ThermoStem platform.

The patent covers the company's allogeneic, off-the-shelf brown adipose-derived stem cell technology, intended to treat obesity and metabolic disorders, it said.

The company said that the patent encompasses therapeutic cells, as well as multiple methods of encapsulation and delivery, including alginate microcapsules, cellulose hydrogels, polymer membranes and advanced scaffolding systems.